Clinical trial
Multicenter Investigator-initiated Phase II Trial of E7090 in Patients With Advanced or Recurrent Solid Tumor With Fibroblast Growth Factor Receptor (FGFR) Gene Alteration (FORTUNE Trial)
NCT04962867 is registered in ClinicalTrials.gov with National Cancer Center, Japan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter Investigator-initiated Phase II Trial of E7090 in Patients With Advanced or Recurrent Solid Tumor With Fibroblast Growth Factor Receptor (FGFR) Gene Alteration (FORTUNE Trial)
- Lead sponsor
- National Cancer Center, Japan
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 15, 2021
- Completion date
- March 31, 2028
- Enrollment
- 75 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
advanced or recurrent solid tumors, fgfr gene alterations